Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTSYNASDAQ:CWBROTCMKTS:GSACOTCMKTS:TRPXD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTSYBiophytis$1.38$2.26$1.38▼$8.00$484K0.842,149 shs27 shsCWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/AGSACGelStat$0.00$0.00$0.00▼$0.00$1.50M3.1310.42 million shs1.30 million shsTRPXDTherapix Biosciences$0.00$2.75▼$22.40$299KN/A1,852 shs900 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTSYBiophytis0.00%0.00%-33.65%-58.93%-76.69%CWBRCohBar0.00%0.00%0.00%0.00%-46.06%GSACGelStat0.00%0.00%0.00%+33.33%0.00%TRPXDTherapix Biosciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTSYBiophytisN/AN/AN/AN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/AGSACGelStatN/AN/AN/AN/AN/AN/AN/AN/ATRPXDTherapix BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTSYBiophytis 0.00N/AN/AN/ACWBRCohBar 0.00N/AN/AN/AGSACGelStat 0.00N/AN/AN/ATRPXDTherapix Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTSYBiophytisN/AN/AN/AN/A($16.18) per shareN/ACWBRCohBarN/AN/AN/AN/A$5.27 per shareN/AGSACGelStatN/AN/AN/AN/AN/AN/ATRPXDTherapix BiosciencesN/AN/AN/AN/A$0.28 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTSYBiophytis-$18.43MN/A0.00∞N/AN/AN/AN/AN/ACWBRCohBar-$12.18MN/A0.00∞N/AN/AN/AN/AN/AGSACGelStatN/AN/A0.00∞N/AN/AN/AN/AN/ATRPXDTherapix Biosciences-$4.79MN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTSYBiophytisN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AGSACGelStatN/AN/AN/AN/AN/ATRPXDTherapix BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTSYBiophytisN/A0.41N/ACWBRCohBarN/AN/AN/AGSACGelStatN/AN/AN/ATRPXDTherapix BiosciencesN/A0.49N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTSYBiophytis0.05%CWBRCohBar2.47%GSACGelStatN/ATRPXDTherapix Biosciences14.32%Insider OwnershipCompanyInsider OwnershipBPTSYBiophytis3.70%CWBRCohBar6.51%GSACGelStat20.50%TRPXDTherapix BiosciencesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTSYBiophytis30351,000338,000N/ACWBRCohBar102.91 millionN/ANot OptionableGSACGelStat23.74 billion2.97 billionNot OptionableTRPXDTherapix Biosciences850,000N/ANot OptionableTRPXD, CWBR, BPTSY, and GSAC HeadlinesRecent News About These CompaniesTRON (CRYPTO: TRX)February 14, 2024 | fool.comPaddle Healthy: TRX WorkoutSeptember 28, 2023 | mensjournal.comDead: RAM 1500 TRXSeptember 24, 2023 | jalopnik.com2024 Ram 1500 TRX Final Edition Brings the EndSeptember 19, 2023 | autoweek.comUsed 2010 Dodge Ram 1500 TRX trucks for sale near meAugust 12, 2023 | cars.comT. Rowe Price Retirement I 2040 IFebruary 23, 2023 | morningstar.comUsed 2022 RAM 1500 TRX trucks for sale in Dallas, TXFebruary 19, 2023 | cars.comThe 2023 Chevy Silverado ZR2 Is More Well-Rounded Than the Raptor or TRXJanuary 1, 2023 | jalopnik.com2022 Ram 1500 TRXOctober 25, 2022 | caranddriver.comTRX-Duo Is A Red Pitaya Clone For Software Defined RadioOctober 13, 2022 | hackaday.comTRPXD, CWBR, BPTSY, and GSAC Company DescriptionsBiophytis NASDAQ:BPTSY$1.38 0.00 (0.00%) As of 06/16/2025Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.CohBar NASDAQ:CWBR$0.41 0.00 (0.00%) As of 01/23/2025CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.GelStat OTCMKTS:GSAC$0.0004 0.00 (0.00%) As of 06/16/2025 09:52 AM EasternGelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.Therapix Biosciences OTCMKTS:TRPXDTherapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 The Bottom Is in for Powerfleet: An Intelligent Time to Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
